drugset
drugset / Trial / NCT04536467

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

NCT04536467 ↗

Phase 2 Unknown 80 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelPrevention

Summary

To Prevent Chemotherapy Induced Ovarian Failure with the gonadotropin-releasing hormone Agonist Goserelin in Young female Lymphoma Cancer patients Receiving Chemotherapy

Timeline

Start
2019-03-01
Primary completion
2020-12-01
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous

Indications

primary ovarian failure